Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M767Revenue (TTM) $M165Net Margin (%)-73.9Altman Z-Score-2.4
Enterprise Value $M749EPS (TTM) $-2.7Operating Margin %-71.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score3.5Pre-tax Margin (%)-74.0Higher ROA y-yY
Price/Book21.210-y EBITDA Growth Rate %--Quick Ratio4.3Cash flow > EarningsN
Price/Sales4.15-y EBITDA Growth Rate %--Current Ratio4.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-59.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-593.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M57.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CHRS is held by these investors:



CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herman Alan C.Chief Scientific Officer 2017-08-08Sell17,535$15.02-11.78view
Herman Alan C.Chief Scientific Officer 2017-07-05Sell600$15-11.67view
Herman Alan C.Chief Scientific Officer 2017-06-01Sell11,333$20.32-34.79view
Herman Alan C.Chief Scientific Officer 2017-05-01Sell11,333$20-33.75view
Herman Alan C.Chief Scientific Officer 2017-04-03Sell11,333$20.73-36.08view
Herman Alan C.Chief Scientific Officer 2017-03-01Sell11,333$24.19-45.23view
Herman Alan C.Chief Scientific Officer 2017-02-01Sell11,333$27.37-51.59view
Viret Jean-FredericCFO 2017-01-25Sell3,900$27-50.93view
Herman Alan C.Chief Scientific Officer 2017-01-03Sell11,333$27.95-52.59view
Viret Jean-FredericCFO 2016-12-16Sell3,900$28.3-53.18view

Press Releases about CHRS :

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th Oct 23 2017 
Coherus BioSciences Provides Update on ‘619 IPR Institution Decision Sep 07 2017 
Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September Sep 01 2017 
Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence S Aug 28 2017 
Coherus Secures Private Placement from Temasek Aug 21 2017 
Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results Aug 07 2017 
Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522 Aug 07 2017 
Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th Jul 24 2017 
Covered Call reports for Amazon.com, Coherus Biosciences, 3D Systems, The Kroger Co and Tesla Motors Jun 12 2017 
Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application Jun 12 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK